Skip to content
Hexocyclium
Tral (hexocyclium) is a small molecule pharmaceutical. Hexocyclium was first approved as Tral on 1982-01-01. It is known to target muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M2, and muscarinic acetylcholine receptor M1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hexocyclium methylsulfate
Tradename
Company
Number
Date
Products
TRALAbbVieN-010599 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03A: Drugs for functional gastrointestinal disorders
— A03AB: Synthetic anticholinergics, quaternary ammonium compounds for functional gastrointestinal disorders
— A03AB10: Hexocyclium
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C67—151411
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517912———2
PhotochemotherapyD01077811———1
Basal cell neoplasmsD01829511———1
Colonic neoplasmsD003110C1811———1
Cervical intraepithelial neoplasiaD018290D06—1———1
Uterine cervical dysplasiaD002578EFO_1000910N8711———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD0105991————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHEXOCYCLIUM
INNhexocyclium metilsulfate
Description
Tral (hexocyclium) is a small molecule pharmaceutical. Hexocyclium was first approved as Tral on 1982-01-01. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M1.
Classification
Small molecule
Drug classquaternary ammonium derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1
Identifiers
PDB—
CAS-ID6004-98-4
RxCUI26867
ChEMBL IDCHEMBL1201325
ChEBI ID5707
PubChem CID24199
DrugBankDB06787
UNII ID84OPZ2Q0VB (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CHRM5
CHRM5
CHRM4
CHRM4
CHRM3
CHRM3
CHRM2
CHRM2
CHRM1
CHRM1
Organism
Homo sapiens
Gene name
CHRM5
Gene synonyms
NCBI Gene ID
1133
Protein name
muscarinic acetylcholine receptor M5
Protein synonyms
acetylcholine receptor, muscarinic 5
Uniprot ID
Q96RG7
Mouse ortholog
Chrm5 (213788)
muscarinic acetylcholine receptor M5 (Q920H4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 18 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
39 adverse events reported
View more details